c-MET Antikörper (pTyr1003) (Cy5.5)

Produktnummer ABIN2177601

Produktdetails anti-c-MET Antikörper (Cy5.5)

Target: c-MET (MET) (Met Proto-Oncogene (MET))

Bindungsspezifität: pTyr1003

Reaktivität: Human, Maus, Ratte

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser c-MET Antikörper ist konjugiert mit Cy5.5

Applikation: Western Blotting (WB)

Kreuzreaktivität: Human

Homologie: Mouse,Rat,Dog,Cow,Sheep,Pig,Horse,Rabbit,Guinea Pig

Aufreinigung: Purified by Protein A.

Immunogen: KLH conjugated synthetic phosphopeptide derived from human c-Met around the phosphorylation site of Tyr1003

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: IF(IHC-P) 1:50-200

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Konzentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Lagerung: -20 °C

Informationen zur Lagerung: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Haltbarkeit: 12 months

Details zu c-MET

Target: c-MET (MET) (Met Proto-Oncogene (MET))

Andere Bezeichnung: Met (C-Met) (MET Produkte)

Synonyme: AUTS9 antikoerper, HGFR antikoerper, RCCP2 antikoerper, c-Met antikoerper, AI838057 antikoerper, HGF antikoerper, Par4 antikoerper, Hgfr antikoerper, c-met antikoerper, MET antikoerper, C-MET antikoerper, met antikoerper, met-A antikoerper, MET proto-oncogene, receptor tyrosine kinase antikoerper, met proto-oncogene antikoerper, MET proto-oncogene, receptor tyrosine kinase L homeolog antikoerper, MET antikoerper, Met antikoerper, met.L antikoerper

Hintergrund:

Synonyms: Met c-Met Tyr1003, AUTS9, c met, cmet, D249, Hepatocyte growth factor receptor, Hepatocyte growth factor receptor Precursor, HGF, HGF receptor, HGF SF receptor, HGF/SF receptor, HGFR, MET, Met proto oncogene tyrosine kinase, Met proto-oncogene hepatocyte growth factor receptor, Met proto-oncogene, Met protooncogene, MET_HUMAN, Oncogene MET, Par4, Proto-oncogene c-Met, RCCP2, Renal cell carcinoma papillary 2 gene, Scatter factor receptor, SF receptor, Tyrosine-protein kinase Met.

Background: c-Met, a member of the tyrosine kinase superfamily, is the receptor for hepatocyte growth factor, also known as scatter factor (HGF/SF). The mature c-Met protein is a disulfide-linked heterodimer with Mr=190 kDa composed of a heavily glycosylated alpha subunit that is completely extracellular in localization, and a beta subunit comprising an extracellular ligand binding domain, a single transmembrane domain, and a cytoplasmic tyrosine kinase domain. Cells expressing c-Met include epithelial cells, endothelial cells, blood cells of various types, and glomerular mesenchymal cells.HGF/SF binding to c-Met stimulates receptor dimerization and the phosphorylation of numerous residues within the receptor?????s cytoplasmic domain. Signaling proteins that are phosphorylated and/or localized in response to c-Met phosphorylation include: Grb2, Shc, Cbl, Crk, cortactin, paxillin, GAB1, PI3K, FAK, Src, Ras, ERK1 and 2, JNK, PLC gamma, AKT, and STAT3. HGF/SF stimulation of c-Met expressing cells enhances proliferation, migration, morphogenesis, and protease synthesis, characteristics that are associated with invasive cell phenotype. Many types of cancer exhibit sustained c-Met stimulation, overexpression, or mutation, including carcinomas of the colon, breast, ovary, lung, liver, prostate, thyroid, kidney, as well as melanomas and sarcomas. In addition to cancer studies, other research areas in which c-Met is under investigation include organogenesis, organ regeneration, angiogenesis and surgical wound healing.

Gen-ID: 4233

Pathways: RTK Signalweg, Carbohydrate Homeostasis, Synaptic Membrane, Signaling of Hepatocyte Growth Factor Receptor